• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib.

作者信息

Zhao Guojiang, Chen Lin, Xiao Mingzhe, Yang Shengli

机构信息

Department of Oncology and Hematology, Panzhihua Central Hospital, Panzhihua, 617000, China.

The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, 210002, China.

出版信息

Lung Cancer. 2021 Feb;152:189-192. doi: 10.1016/j.lungcan.2020.12.013. Epub 2020 Dec 14.

DOI:10.1016/j.lungcan.2020.12.013
PMID:33419583
Abstract
摘要

相似文献

1
Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib.一名对克唑替尼有反应的肺腺癌患者罕见地同时存在三种新型CDCA7-ALK、FSIP2-ALK、ALK-ERLEC1融合基因。
Lung Cancer. 2021 Feb;152:189-192. doi: 10.1016/j.lungcan.2020.12.013. Epub 2020 Dec 14.
2
Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib.一名肺腺癌患者中新型RGS18下游基因间区域ALK融合与THUMPD2-ALK融合的共存及对克唑替尼的反应
Lung Cancer. 2021 Apr;154:216-218. doi: 10.1016/j.lungcan.2021.02.008. Epub 2021 Feb 16.
3
Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.下一代测序在肺腺癌中鉴定出一种对克唑替尼敏感的新型WDPCP-ALK融合基因。
Clin Lung Cancer. 2019 Sep;20(5):e548-e551. doi: 10.1016/j.cllc.2019.06.001. Epub 2019 Jun 14.
4
Melanoregulin-Anaplastic Lymphoma Kinase (ALK), a Novel ALK Rearrangement That Responds to Crizotinib in Lung Adenocarcinoma.黑素调节蛋白-间变性淋巴瘤激酶（ALK），一种在肺腺癌中对克唑替尼有反应的新型ALK重排。
J Thorac Oncol. 2020 Mar;15(3):e44-e46. doi: 10.1016/j.jtho.2019.11.019.
5
Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib.一名肺腺癌患者中新型PRKCB-ALK、EML4-ALK双融合的共存及对克唑替尼的反应
J Thorac Oncol. 2019 Dec;14(12):e266-e268. doi: 10.1016/j.jtho.2019.07.021.
6
A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.一名转移性肺腺癌患者中存在新型 SOS1-ALK 融合变体，对克唑替尼有显著反应。
Lung Cancer. 2020 Apr;142:59-62. doi: 10.1016/j.lungcan.2020.02.012. Epub 2020 Feb 21.
7
A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma.在一名肺腺癌患者中，CENPA与DPYSL5-ALK外显子20融合变体之间的一个新型基因间区域对克唑替尼治疗有反应。
J Thorac Oncol. 2019 Sep;14(9):e191-e193. doi: 10.1016/j.jtho.2019.04.012.
8
A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.一种在肺腺癌中出现的对克唑替尼耐药的新型HIP1-ALK融合变体。
Lung Cancer. 2021 Jan;151:98-100. doi: 10.1016/j.lungcan.2020.11.014. Epub 2020 Nov 23.
9
The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.ALK 重排肺腺癌中 TNIP2-ALK 融合变体对克唑替尼的临床反应。
Lung Cancer. 2019 Nov;137:19-22. doi: 10.1016/j.lungcan.2019.08.032. Epub 2019 Aug 31.
10
Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib.Chr2 30297612-ALK，一种与ALK外显子18的新型基因间融合，对克唑替尼有反应。
Clin Lung Cancer. 2020 Nov;21(6):e564-e566. doi: 10.1016/j.cllc.2020.04.014. Epub 2020 May 6.

引用本文的文献

1
Coexistence of a novel , double-fusion in a lung poorly differentiated adenocarcinoma patient and response to alectinib: a case report and literature review.一名肺低分化腺癌患者中新型双融合的共存及对阿来替尼的反应：病例报告与文献综述
Front Oncol. 2024 Dec 13;14:1453259. doi: 10.3389/fonc.2024.1453259. eCollection 2024.
2
Dysregulated Immune and Metabolic Microenvironment Is Associated with the Post-Operative Relapse in Stage I Non-Small Cell Lung Cancer.免疫和代谢微环境失调与I期非小细胞肺癌术后复发相关。
Cancers (Basel). 2022 Jun 22;14(13):3061. doi: 10.3390/cancers14133061.
3
Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes.
在大规模肺癌人群中对激酶基因间断点重排进行特征描述及真实世界临床结局。
ESMO Open. 2022 Apr;7(2):100405. doi: 10.1016/j.esmoop.2022.100405. Epub 2022 Mar 16.
4
Development and validation of an RNA sequencing panel for gene fusions in soft tissue sarcoma.软组织肉瘤基因融合 RNA 测序 panel 的开发与验证。
Cancer Sci. 2022 May;113(5):1843-1854. doi: 10.1111/cas.15317. Epub 2022 Mar 10.